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Abstract: The use of meta-analysis has become increasingly useful for clinical and policy 
decision making. A recent development in meta-analysis, multiple treatment comparison (MTC) 
meta-analysis, provides inferences on the comparative effectiveness of interventions that may 
have never been directly evaluated in clinical trials. This new approach may be confusing for 
clinicians and methodologists and raises specific challenges relevant to certain areas of medicine. 
This article addresses the methodological concepts of MTC meta-analysis, including issues 
of heterogeneity, choice of model, and adequacy of sample sizes. We address domain-specific 
challenges relevant to disciplines of medicine, including baseline risks of patient populations. 
We conclude that MTC meta-analysis is a useful tool in the context of comparative effective-
ness and requires further study, as its utility and transparency will likely predict its uptake by 
the research and clinical community.
Keywords: network, multiple treatment comparison, mixed treatment comparison, 
  meta-analysis
Introduction
New methods of evaluating the relative effectiveness of competing interventions may 
provide unique opportunities for comparative effectiveness research. As the utility of 
meta-analysis grows in popularity, so too does it grow in the complexity of methods 
and questions that it aims to answer.1 An increasingly common challenge to deci-
sion makers is to infer which of several competing interventions is likely to be most 
  effective. This is particularly challenging when the interventions have not been directly 
evaluated in well-conducted randomized clinical trials (RCTs). This is referred to as 
an indirect comparison.2
Although meta-analysis has been used in clinical medicine since the 1980s3,4 and 
became commonly used in the 1990s, possibly due to the establishment of the Cochrane 
Collaboration,5 the methods to refine, reduce bias, and improve meta-analysis have 
developed slowly.1 Standard meta-analyses have typically investigated the effect of 
an intervention against a control, typically a placebo or another active intervention. 
  However, such an analysis provides no inference into the relative effect of one inter-
vention over another intervention that has not been compared directly in an RCT. The 
adjusted indirect comparison, first reported by Bucher et al,6 developed initial methods 
to make indirect comparisons and has since been extended to the multiple treatment 
comparison (MTC) meta-analysis, to provide more sophisticated methods for quanti-
tatively addressing indirect comparisons of several competing interventions.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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The MTC approach, based on developing methods by sev-
eral investigators,7–9 is a generalization of standard pair-wise 
meta-analysis for drug A versus drug B trials, to data structures 
that include, for example, A versus B, B versus C, but no A 
versus C evaluation (Figure 1). The MTC requires that there is a 
network of pair-wise comparisons that connects each interven-
tion to every other treatment. This approach can only be applied 
to connected networks of RCTs and has two important roles: i) 
strengthening inference concerning the relative efficacy of two 
treatments by including both direct and indirect comparisons 
of these treatments, and ii) facilitating simultaneous inference 
regarding all treatments, in order to simultaneously compare, 
and potentially rank, these treatments.7 The MTC approach 
yields several advantages over other indirect comparison 
approaches, such as those proposed by Bucher et al6 and Song 
et al,10 as it can deal with large numbers of indirect comparisons 
during a single analysis and can improve statistical power by 
combining both direct and indirect evidence.11,12
However, despite the sophistication and desirability of a 
network of compared trials,13 the MTC approach is hampered 
by several important concerns. First, it is a relatively new 
approach that is most commonly conducted in a Bayesian 
framework and will necessitate familiarity with Bayesian 
software (eg, WinBUGS [WinBUGS Project, Cambridge, UK] 
and R2BUGS [R2BUGS project, Columbia University, NY]). 
Second, the basic assumptions underlying the MTC approach 
are more complex than the assumptions concerning the standard 
pair-wise meta-analysis approach, and these are typically not 
well defined. Finally, interpreting MTC outputs may be mis-
leading, as assessments of heterogeneity and statistical power 
are not commonly employed, resulting in a “black box” effect 
of the analysis. Assuming that these concerns can be overcome, 
MTCs are a powerful tool for decision making in medicine.
The aim of this article is to describe some of the   current 
challenges of MTC for readers who are familiar with 
  meta-analysis. We have chosen to illustrate the novelty and 
challenges of this approach in oncology medicine, although 
its use is not limited to any specific field of medicine. 
We chose oncology because it is a very well-funded area of 
medicine that frequently reports clinical trials and regularly 
has major clinical advances. We then describe in more detail 
some of the assumptions underlying MTC methods and 
  interpretations. We finally discuss specific challenges that 
readers and the methodological community may consider if 
MTC is to be widely understood.
Multiple treatment comparison 
meta-analyses in oncology
Despite the high profile and large number of clinical trials 
in oncology, there have been relatively few MTC meta-
analyses conducted within this field. This is likely to be for 
two reasons: first, MTC is a new and sophisticated approach 
to meta-analysis that has yet to gain much popularity in the 
general academic community, most likely due to its statisti-
cal complexity; and, second, conducting MTC in cancer 
identifies unique, disease-specific challenges, due to both 
a rapidly changing therapeutic armory and progressive 
understanding of the disease and underlying risks. Using a 
systematic search of the medical literature with the search 
terms   “(network OR multiple treatment comparison OR 
mixed treatment   comparison)” and “meta-analysis”, up 
to January 2010, we identified six published MTC meta-
analyses conducted in the field of oncology (Table 1). As the 
table displays, these analyses range from simple to very 
complex. In this article we discuss the challenges and some 
solutions to interpreting and conducting clinically relevant 
MTC analysis.
Issues of methods
Assumptions of an MTC analysis
When conducting a standard pair-wise meta-analysis of 
RCTs comparing two interventions, we assume that included 
trials are broadly similar in terms of interventions tested 
and the expected direction of intervention effects across 
included patient populations. This similarity assumption is 
also required when conducting an MTC analysis aiming to 
compare more than two interventions.
In addition to trial similarity, effect size similarity is 
also of concern in a standard pair-wise meta-analysis of 
RCTs. The most common methods for pooling studies in 
a meta-analysis are the fixed- and random-effects models. 
P
P C
A B
A A BB
Example 3
Example 1
Example 2
Figure 1 Direct and indirect comparisons. Circled letters represent trial arms of drug 
A (A), drug B (B), drug C (C), and placebo (P). Flat lines represent direct trials, dotted 
lines represent indirect comparisons. Example 1: Direct comparison of drug A and drug 
B. Example 2: Adjusted indirect comparison where drug A and drug B have not been 
evaluated directly. Example 3: A multiple treatment comparison where drug A and drug 
C, drug B and placebo, and drug C and placebo have not been evaluated directly.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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An assumption of fixed effects is that the effect size is the 
same across studies and the observed variability results from 
chance alone. This is commonly referred to as the statisti-
cal homogeneity assumption.14 Although several common 
interpretations exist,15 usually, an assumption of random 
effects is that there may be genuine diversity in the results 
of various trials owing to differences between these trials in 
study and patient characteristics, so a between-study variance 
component is incorporated into the calculations to capture this 
diversity (commonly referred to as statistical heterogeneity). 
When there is no observed between-study heterogeneity, the 
fixed- and random-effects approaches coincide. Otherwise, 
the random-effects approach provides wider confidence 
intervals (CIs) for the relative intervention effect and is 
thus considered more clinically conservative.16 Although a 
random-effects approach explicitly models between-study 
heterogeneity, it does not explain it. Attempts to explain the 
between-study heterogeneity would have to rely on meta-
regression, a technique that allows one to study whether 
or not relevant trial-level covariates act as modifiers of the 
relative intervention effect.
In an MTC analysis, the assumptions made about statisti-
cal heterogeneity are of prime importance, as assessments 
of heterogeneity are not yet established and conventional 
measurements of heterogeneity do not exist (ie, τ2 or I  2). 
Note that in this setting, one would need to consider the 
issue of statistical heterogeneity in relation to each possible 
pair-wise comparison of interventions.
Clinical heterogeneity may induce statistical   heterogeneity. 
In a recent MTC analysis involving 60 RCTs of cancers of 
unknown sites published between 1971 and 2006,17 the 
populations range from poor-risk patients who had received 
previous therapy to   favorable- and intermediate-risk patients 
as time progressed (a 6% performance status improvement 
per decade). Therefore, clinicians will need to determine 
for themselves whether the underlying risk of events is 
sufficiently similar across time. This appears to be an issue 
across differing diseases, as an MTC examining breast 
cancer,19 including trials from 1971 to 2007, demonstrated 
changing disease risks over time. This possibly reflects the 
cointerventions that improve outcomes for patients and that 
have been used for breast cancer since 1971.20
Methodological heterogeneity may also induce statisti-
cal heterogeneity. Therefore, in addition to intervention and 
clinical similarities, the MTC analysis requires an assumption 
of similarity on methodological grounds. In particular, are 
trials measuring a similar estimate of effect? Is the length 
of follow-up sufficiently similar? Are adjuvant therapies 
considered? Were any trials stopped early?21–23 Are doses 
of the intervention sufficiently similar? In many cases, 
  differences across trials do not result in meaningful discrep-
ancies in pooled results, and an MTC should not be any more 
conservative in terms of inclusion criteria than any other 
  meta-analysis.24 However, without consideration of these 
issues, it may be impossible to determine whether and where 
biases are affecting results. Song et al25 have demonstrated 
that pooled indirect comparisons may, in some circumstances, 
provide less biased estimates of treatment effects than pooled 
direct (head-to-head) comparisons.
In the circumstance that both direct and indirect evi-
dence is available in an MTC analysis (when the network 
of treatments in the MTC analysis includes at least one 
“closed” loop, where all interventions are connected in 
a network), it is possible to assess the consistency in treat-
ment effects observed through the two comparisons by 
assessing the coherence (or incoherence) of the treatment 
estimates. Incoherence tells us whether the effect estimated 
from indirect comparisons differs from that estimated from 
direct comparisons.7,9 In a meta-analysis addressing smoking 
cessation,26 two head-  to-head trials resulted in superiority of 
varenicline over bupropion (odds ratio [OR] 1.49, 95% CI 
1.49–2.33, P , 0.001), with similar effects in the indirect 
comparison of nine trials of varenicline and 31 trials of bupro-
pion (OR 1.40, 95% CI 1.08–1.85, P , 0.01), displaying 
reasonable coherence. Although coherence can be explored 
through formal hypothesis testing, resulting in a significant 
or nonsignificant result (yes/no), a critical assessment of why 
incoherence may exist may represent a more reasonable and 
useful strategy for assessing the impact of incoherence.27,28 
Given that this type of hypothesis testing can suffer from 
low power as well from a lack of balance,27 Dias et al29 have 
proposed two sophisticated methods for checking consistency 
in an MTC analysis, which rely on back-calculation and node-
splitting, respectively. The back-calculation method can be 
used for summary-level data, and the node-splitting method 
can be used for trial-level data. Trials identified on the basis 
of these methods as contributing the most to inconsistency 
should be excluded from the MTC analysis in order to achieve 
consistency.29
To summarize, at least three issues of combinability need 
to be considered: a homogeneity assumption for each meta-
analysis, a similarity assumption for individual comparisons, 
and a consistency assumption for the combination of evidence 
from different sources.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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Assessing the heterogeneity of included 
trials in an MTC analysis
As with standard pair-wise meta-analysis, the assumption 
that trials include similar populations, methodological 
approaches, and interventions should be assessed using both 
visual assessment and, where possible, an assessment of 
statistical homogeneity. As no formal statistical tools exist 
for evaluating statistical heterogeneity in an MTC analysis, 
we suggest several possible steps here.
The first step involves assessing the statistical heterogene-
ity for each direct pair-wise comparison before conducting 
the MTC analysis. Specifically, for pair-wise comparisons 
where sufficient direct evidence is available, one can compute 
measures of between-study (statistical) heterogeneity in the 
context of standard pair-wise meta-analyses (eg, I2). Because 
MTC typically assumes that statistical heterogeneity is con-
stant between different pair-wise treatment comparisons, 
one could contrast these measures of heterogeneity across 
the relevant treatment comparisons to get a sense of whether 
or not this assumption is tenable. This approach is of limited 
use when the measures of heterogeneity are computed from 
a small number of studies, as these measures would likely 
be unreliable.
A second strategy for gauging whether or not to take 
into account between-study (statistical) heterogeneity when 
performing an MTC analysis is to fit both a fixed-effect and 
a random-effects MTC model to the data and then compare 
the resulting model fits using a measure of model fit adjusted 
for model complexity (eg, deviance information criterion).29 
Although the fixed-effect MTC model assumes that there is 
no between-study heterogeneity, the random-effects MTC 
model would allow for between-study heterogeneity but 
would assume that this heterogeneity is constant across the 
different pair-wise treatment comparisons. If no substantial 
difference can be detected between the two model fits (ie, if 
the difference in the deviance information criterion for the 
two models would not exceed three points), heterogeneity 
may be low.
In some situations, it may be possible to relax the assump-
tion of constant between-study heterogeneity across distinct 
pair-wise intervention comparisons and consider a random-
effects MTC model that allows this heterogeneity to be dif-
ferent across these comparisons.29 The latter type of model 
could be compared against the random-effects MTC model 
introduced previously via the deviance information criterion 
to determine which assumption is more sensible for the data: 
constant or nonconstant between-study   heterogeneity across 
pair-wise intervention comparisons. This would constitute 
the third strategy for evaluating heterogeneity in an MTC 
analysis.
The influence of methodological approach
With indirect and MTC comparisons in their infancy, it is 
not surprising that there has been little comparison between 
the influence of the different approaches on the   estimation 
of   relative intervention effects. The adjusted indirect 
  comparison enables the construction of an indirect estimate 
of the relative effect of two interventions A and B by using 
information from RCTs comparing each of these interven-
tions against a common comparator C (eg, A vs C and 
B vs C).6 The MTC, in contrast, enables the incorporation of 
direct comparisons of A versus B with indirect comparisons 
(A vs C and B vs C) to strengthen the inference of results.7 
The MTC is a statistically more flexible approach and allows 
incorporation of various analyses at the same time. It is, 
however, often more complicated to implement and validate 
than adjusted indirect comparisons.
The influence of using each approach will be different 
depending on the data available, particularly in situa-
tions where both direct and indirect evidence is available. 
O’Regan et al11 have recently provided a comprehensive 
review of the influence of the different approaches in 
seven scenarios, each pertaining to a different number of 
trials with direct and indirect comparisons. Their findings 
demonstrate that depending on the evidence, the indirect 
and MTC comparisons can provide different results. In the 
scenario where all direct pair-wise comparisons involve 
a common comparator (corresponding to star-shaped 
  networks of interventions), they found the results of these 
two approaches to be similar. However, where the network 
of trial evidence becomes more complicated, the MTC is 
more appropriate, as it enables the incorporation of more 
evidence, often reducing the variance in results. As a result, 
we have a starting point for selecting the most appropriate 
approach.
Information size
Precision and adequacy of sample size
An increasingly recognized weakness of pair-wise meta-
analysis is the inadequate power or precision to confirm 
or refute some important intervention effects when only 
a few studies with a small number of events are available.30 
A growing body of work has provided evidence that about 
15%–30% of such meta-analyses are prone to yield spurious Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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inferences in the form of false-positive results or important 
overestimates of treatment effects.31–34 This is particularly 
problematic for MTC analyses, where several different 
interventions are being assessed and where authors may 
choose to rank the effectiveness of interventions according 
to probability values. For example, if three treatments, A, 
B, and C, are being compared in an MTC and all treatments 
have been compared head to head in a few RCTs, there is a 
considerable risk that one of the three pooled head-to-head 
treatment comparisons will yield an over- or underestimate 
of the comparative treatment effect due to the play of chance 
(imprecision). The scenario is less problematic if the indirect 
evidence adds sufficient precision to “correct” the spurious 
estimate. Unfortunately, indirect evidence is typically very 
imprecise. Glenny et al2 have recommended a rule of thumb 
that four RCTs contributing to an indirect comparison are 
required to approximately match the precision that a single 
direct (head-to-head) trial would contribute. When the num-
ber of trials included for the different treatment comparisons 
is unbalanced (eg, three trials compare A with B, but nine 
trials compare A with C), four trials are likely to be an under-
estimate.27 Hence, a spurious result due to imprecision within 
one treatment comparison is likely to contaminate the overall 
inferences drawn from the MTC.34 Given this circumstance, 
the precision of estimates may be affected by a few imprecise 
comparative treatment effect estimates.
Trial-level challenges
The issue of crossing over
In any clinical study, we should aim to evaluate patient-
important outcomes. In many cases of disease, patients 
and their families are most concerned about quality of life 
and mortality. Oncology is one of the most funded fields of 
medicine, and there are many large trials published. However, 
using overall survival as an endpoint in cancer clinical trials 
may be an elusive goal. Although arguably objective and 
easy to measure, it is limited by requiring extended patient 
follow-up and being confounded by disease progression that 
may be unrelated to site-specific cancer.35–37 Further, as new 
therapies may provide effectiveness along a continuum of the 
disease, patient survival may be influenced as to whether they 
received adjunct therapies after randomization. It is common 
in cancer clinical trials that a failing patient crosses over (also 
called crossing in) to either the intervention under investiga-
tion or another salvage therapy, thus obfuscating the effect of 
the study drug on overall survival.36,38 As a result, most RCTs 
are underpowered to assess overall survival.36
The largest challenge to employing overall survival as a 
study primary endpoint is that clinicians typically want to 
exhaust treatments in order to sustain a patient’s life, regard-
less of participation in a clinical trial. A patient who does not 
respond to the trial intervention may seek or be provided with 
the alternative study drug or an alternative existing or experi-
mental treatment. However, when a patient crosses over to 
receive the intervention treatment, the extent of carryover 
effect or the contribution of a new treatment to hastening 
mortality cannot be known. In addition, the patient’s mor-
tality status is frequently removed from the group they were 
assigned to. The following example exemplifies this concern. 
In a trial of tamoxifen or letrozole for first-line treatment in 
postmenopausal patients with endocrine-responsive advanced 
breast cancer, letrozole was significantly more effective than 
tamoxifen for response rates and time to tumor progression.39 
However, no important differences in overall survival existed 
between the study arms. But when a sensitivity analysis 
censored patients who crossed over to the other study drug, 
the results indicated that the use of letrozole was associated 
with a survival benefit.40
Although crossing over in cancer clinical trials is com-
mon, methods with which to deal with overall survival in the 
analysis of individual RCTs and meta-analysis are not well 
established.35,41 A clinical trial may consider a crossover as 
a failure of treatment (included in a progression of disease 
analysis) or may exclude a patient from analysis, as a result 
losing the benefits of the intent-to-treat principle.42 Despite the 
fact that these are RCTs, such crossing over may not occur 
randomly across arms, as one treatment may be genuinely 
more beneficial than the other. In meta-analysis, the inclusion 
of crossed-over patients represents an important challenge. 
  Principally, the benefits of randomization are lost on the 
patients who crossed over. If this is a small number of patients 
in a moderate to large trial, the effects may be small.   However, 
if this is a large number of patients, the overall survival analy-
sis could be seriously biased in a meta-analysis. Further, the 
effects of the patient’s previous treatment (period A) may 
have a differing effect on response to the second treatment 
(period B), akin to the carryover concept in a crossover trial.43   
It is possible that the survival endpoint remains valid if the trial-
ists aim to determine what regimen or strategy (ie, what drug 
to start with) of first-line therapies provides overall survival 
benefits. However, this becomes increasingly confusing as 
patients switch from drug A to drug B or drug C/D. A common 
approach is to censor these patients from the survival analysis. 
However, this will bias a survival assessment, as the true time Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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point for   progression of that patient is replaced by the time 
points of patients who were free of disease when that patient 
was censored, favoring the less effective intervention.41,44 
A meta-analyst aiming to calculate a relative risk based on 
event rates would typically not have this information from a 
publication, and pooling hazard ratios may improperly ignore 
this issue. It seems appropriate that meta-analysis reports 
whether crossed-over patients could create bias, just as large 
loss to follow-up may.45 Some study designs and opinions do 
not permit a crossover of patients to the intervention arm if a 
patient fails first-line therapy.41,46 However, this creates dilem-
mas for clinicians and trialists, especially regarding patients 
with a poor survival prognosis or those for whom alternative 
experimental drugs may exist.
Issues pertaining to the use of patients’ 
characteristics
The requirement of evidence to inform decisions regarding 
health technologies has been a leading motivation in the 
development of indirect and MTC approaches. It is therefore 
not surprising that pragmatic decision makers have sought 
to identify characteristics or subgroups of patients in whom 
technologies may have greater benefit of improved safety.
As described previously, conventional meta-analysis 
requires included trials to be sufficiently homogeneous, but 
MTC approaches have an additional requirement that tri-
als are similar for moderators of relative treatment effect.25 
Song et al10 state that the average relative effect estimated in 
placebo-controlled trials of one therapy should be generaliz-
able to patients in placebo-controlled trials of an alternative 
therapy, and vice versa. The role of meta-regression and 
subgroup analysis in circumstances where heterogeneity 
between sources of evidence is present can play a greater role 
than in conventional meta-analysis by enabling   comparisons 
between “similar” groups.10 However, the pitfalls of subgroup 
analysis, meta-regression, and meta-analysis acknowl-
edged in the conventional meta-analysis literature47,48 will   
carry through to indirect and MTC approaches, and, as a 
  consequence, authors are recommended to use predefined 
characteristics and interpret the results cautiously.
We did not find examples of meta-regression in MTC for 
oncology. However, an example of meta-regression from one 
of the authors examined the effectiveness of biologic agents 
in rheumatoid arthritis.49 In this example, baseline disease   
duration, a characteristic known to be related to the effective-
ness of biologics versus standard treatments, was included 
in the MTC in the form of a meta-regression. Although the 
inclusion of the meta-regression did not change the signifi-
cance of the results, it did modify the odds to suggest that the 
three tumor necrosis factor antagonists etanercept, infliximab, 
and adalimumab were very similar, a result that has long been 
suspected in the wider literature (Figure 2).
Adjustments for baseline characteristics known to be pre-
dictive of survival and progression-free survival, such as the 
level of circulating tumor cells in metastatic breast cancer, are 
obvious candidates for the use of meta-regression in MTC.50 
Another use is the adjustment of doses where different tri-
als have used various dosages of the same treatment. Where 
a dose-response relationship exists, meta-regression within 
an MTC can potentially overcome issues where RCTs have 
used potentially inadequate dosages.8
Using Bayesian priors to deal  
with challenging situations
Although indirect and MTC comparisons have been conducted 
from the frequentist approach,9,51 the Bayesian approach has 
Without meta-regression Without meta-regression
Etanercept vs Anakinra
Infliximab vs Anakinra
Infliximab vs Etanercept
Adalimumab vs Infliximab
Adalimumab vs Etanercept
Adalimuab vs Anakinra
0123 0123
Odds ratio of a ACR50 Odds ratio of a ACR50
Figure 2 Use of baseline adjustments versus crude analysis in rheumatoid arthritis multiple treatment comparison meta-analysis.49 Legend: American College of Rheumatology 
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been increasingly promoted as a more flexible method for 
incorporating “knowledge” into the results.52 In the literature, it 
is common to see the use of   “noninformative” priors (essentially 
assuming complete uncertainty), and the Bayesian approach 
is used for other purposes, such as enabling treatments to be 
ranked so that the probability of any one treatment being “best” 
can be obtained and used in economic evaluation.53 However, 
the use of informed priors provides a basis for dealing with 
situations where there is inconsistency in results from differ-
ent trials, trials included have not reported results, and where a 
sparse network makes estimating heterogeneity challenging.
Bayesian statistics are poorly understood by clinicians and 
many statisticians. The use of prior knowledge can change the 
interpretation of a study or can provide increasing confidence 
in the results. For example, a recent analysis of pivotal trials of 
adjuvant chemotherapy in nonsmall cell lung cancer produced 
positive results that were at odds with previous studies.54 To 
deal with the problem of how to interpret the results of the 
new studies, the authors examined different priors: assume 
adjuvant chemotherapy has no benefit, use skeptical priors 
(which essentially add pessimism to the positive results of 
the new findings), and use expert beliefs. The results con-
sistently found that by combining the evidence, adjuvant 
chemotherapy was effective in all scenarios, giving greater 
confidence in the results.
Discussion
This paper aims to inform readers who may be exposed to 
reading MTC analyses as manuscripts or contributing to 
them as investigators. Although we have found only a few 
examples of MTC in the oncology literature at present, with 
further consideration of some of the issues presented, it is 
anticipated that there will be more widespread use of MTC 
in the future. Although we believe that MTC has an impor-
tant role to play, we are cautious that readers and users of 
this methodology are clear of both the assumptions and the 
benefits over conventional meta-analysis.
Two issues related to the way MTCs are interpreted are 
worthy of further consideration. The first regards the level of 
evidence an MTC can provide. The Grading of Recommenda-
tions, Assessment, Development and Evaluation (GRADE) 
working group, that proposes methods for evaluating the 
strength of inference of observational studies, RCTs, and 
meta-analysis, has considered MTC.55,56 In an upcoming paper, 
the working group considers an MTC analysis as a weaker 
comparison than head-to-head meta-analysis, as differences 
in study methods may contribute to differing estimates of 
treatment effect and result in probably larger treatment effects.   
The basis for this consideration is that because the similarity 
assumption required for MTC is always in some doubt, the 
level of quality of the evidence is downgraded. The working 
group recommends grading down further if the similarity 
assumption is unconvincing
A second issue relates to the way results are translated. 
It is increasingly common for authors of MTC to augment 
their results based on estimates of risk to the use of prob-
abilities, enabling the ranking of treatments for a particular 
outcome. This approach has obvious appeal for lay readers 
of an analysis, providing simple knowledge translation rather 
than statistical outcomes. The concern is that such rankings 
overinterpret results that authors acknowledge to contain 
errors and biases occurring from the statistical approach and 
synthesis of evidence.
Conclusion
In conclusion, the appropriate use and interpretation of 
MTC will provide the methodological community and 
wider medical community with information to guide deci-
sions. Further methodological research in MTC is required 
to overcome concerns related to their transparency and 
interpretability.
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